Gamble

Gamble Therapeutics is a precision medicine biotechnology company focused on developing novel therapeutics that target long non-coding RNA (lncRNA) to treat aggressive forms of cancer. The company's proprietary platform identifies specific lncRNAs that drive tumor progression and metastasis, particularly in indications with high unmet needs such as triple-negative breast cancer. By utilizing small molecules to disrupt the function of these regulatory RNA molecules, Gamble aims to provide new treatment options for patients who have exhausted standard therapies. The company was founded by industry veterans with experience in RNA therapeutics and is currently advancing its lead programs through the pre-clinical stage.